Analytical range LOQ [Bioanalytics]

posted by Farmacevt – North Macedonia, 2021-12-22 23:02 (909 d 13:21 ago) – Posting: # 22711
Views: 2,394

Thanks,
But when you say:

❝ At one extreme you may need to eliminate those subject periods that are affected, which may mean a complete loss of a subject for stats if this is a 222BE design, since only subjects who contribute with T and R should be in the stats analysis.


What is the rational for eliminating those subjects? According to my opinion excluding these subjects can not show that the subjects might have had pre-dose concentration below the LOQ with the given method. It will only reduce the power of the study, isn't it?


Edit: Standard quotes restored; see also this post #8[Helmut]

Complete thread:

UA Flag
Activity
 Admin contact
23,058 posts in 4,840 threads, 1,641 registered users;
124 visitors (1 registered, 123 guests [including 13 identified bots]).
Forum time: 13:24 CEST (Europe/Vienna)

Even though it’s applied science we’re
dealin’ with, it still is – science!    Leslie Z. Benet

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5